RTW Biotech Opportunities (LSE:RTW) Revenue: $250.9 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:RTW RTW Biotech Opportunities Ltd LSE:RTW
41 GF Score
Price $2.43
! 2 Warning Signs
View Full Analysis

What is RTW Biotech Opportunities Revenue?

RTW Biotech Opportunities LSE:RTW 41 Revenue is $250.9 Mil as of Dec. 2025. GuruFocus rates LSE:RTW with a GF Score™ of 41/100. The stock has 2 warning signs investors should review.

RTW Biotech Opportunities's revenue for the six months ended in Dec. 2025 was $288.5 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $250.9 Mil. RTW Biotech Opportunities's Revenue per Share for the six months ended in Dec. 2025 was $0.66. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.55.

During the past 12 months, the average Revenue per Share Growth Rate of RTW Biotech Opportunities was 416.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 8 years, RTW Biotech Opportunities's highest 3-Year average Revenue per Share Growth Rate was -18.10% per year. The lowest was -18.10% per year. And the median was -18.10% per year.


RTW Biotech Opportunities  (LSE:RTW) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


RTW Biotech Opportunities Revenue Related Terms


RTW Biotech Opportunities Revenue Historical Data

* Premium members only.

The historical data trend for RTW Biotech Opportunities's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RTW Biotech Opportunities Revenue Chart

RTW Biotech Opportunities Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial -60.92 -36.51 86.30 38.73 250.89

RTW Biotech Opportunities Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.41 87.90 -49.17 -37.58 288.47

LSE:RTW vs BLK, BX, KKR: Revenue Comparison

For the Asset Management subindustry, RTW Biotech Opportunities's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RTW Biotech Opportunities Revenue vs Asset Management Industry

For the Asset Management industry and Financial Services sector, RTW Biotech Opportunities's Revenue distribution charts can be found below:

* The bar in red indicates where RTW Biotech Opportunities's Revenue falls into.


LSE:RTW
41GF Score
RTW Biotech Opportunities Ltd LSE:RTW
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RTW Biotech Opportunities Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $250.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $250.9 Mil mean?
RTW Biotech Opportunities (LSE:RTW) has a Revenue of $250.9 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on RTW Biotech Opportunities and its competitors.
Is RTW Biotech Opportunities' Revenue too high?
RTW Biotech Opportunities' current Revenue is $250.9 Mil. Overall, RTW Biotech Opportunities has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' Revenue compare to BLK and BX?
RTW Biotech Opportunities' Revenue of $250.9 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for an Asset Management company?
A good Revenue depends on the Asset Management industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on RTW Biotech Opportunities and its competitors. RTW Biotech Opportunities's current Revenue is $250.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current Revenue of $250.9 Mil. The current Revenue is $250.9 Mil. RTW Biotech Opportunities' overall GF Score™ is 41/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current Revenue is $250.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RTW Biotech Opportunities Business Description

Address St Julian’s Avenue, 1st Floor, Royal Chambers, St Peter Port, GGY, GY1 3JX
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
41GF Score

Get the complete analysis for LSE:RTW

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.43
Price